Company news

Enlivex Ltd. news in 2021

Enlivex Ltd.'s news releases, calls and decks from 2021, newest first.

View company

Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece

December 12, 2021

Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

December 6, 2021

Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update

November 21, 2021

Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain

November 9, 2021

Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells

October 4, 2021

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis

October 3, 2021

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

September 21, 2021

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

August 8, 2021

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

August 1, 2021

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

July 11, 2021

Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

June 14, 2021

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

May 31, 2021

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

May 17, 2021

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

March 21, 2021

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies

March 7, 2021

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

February 28, 2021

Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares

February 17, 2021

Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy

February 15, 2021

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

February 11, 2021

Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares

February 8, 2021

Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

February 2, 2021

Decks in 2021